Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 3 5 W ELECTROLYTES IN DEXTROSE 25 IN PLASTIC CONTAINER versus AMINOSYN II 3 5 W ELECTROLYTES IN DEXTROSE 25 W CALCIUM IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 3 5 W ELECTROLYTES IN DEXTROSE 25 IN PLASTIC CONTAINER versus AMINOSYN II 3 5 W ELECTROLYTES IN DEXTROSE 25 W CALCIUM IN PLASTIC CONTAINER.
AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER vs AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amino acids provide substrates for protein synthesis and metabolic processes; dextrose supplies glucose for energy; electrolytes maintain fluid and electrolyte balance.
Provides essential amino acids and dextrose for parenteral nutrition; amino acids serve as substrates for protein synthesis, while dextrose supplies caloric energy.
Intravenous infusion: 500 mL/day initially, titrate to provide 1.5-2 g/kg/day of amino acids and 25-50 g/kg/day of dextrose; monitor electrolytes.
Individualized based on protein and calorie requirements; typical adult dose: 500-2000 mL/day intravenously, infused at a rate not exceeding 200 mL/hour.
None Documented
None Documented
Amino acids: 0.5-2 hours (rapid clearance); dextrose: ~1-2 hours (insulin-dependent). Clinical context: Continuous IV infusion maintains steady state.
Variable, dependent on individual amino acids and metabolic state; clinical context reflects continuous infusion without distinct terminal phase.
Renal (amino acids: ~80% reabsorbed, excess excreted unchanged; dextrose: primarily metabolized, small fraction excreted renally <5%; electrolytes: renal excretion proportional to intake and plasma levels).
Renal, primarily as urea and free amino acids; minimal biliary/fecal elimination.
Category C
Category C
Amino Acid Solution
Amino Acid Solution